MIRM News and Press, Mirum Pharmaceuticals Inc. From 09/05/23

Mirum has acquired Travere’s rights and assets related to Cholbam ® and Chenodal ® Travere received $210 million at closing and is eligible for up to $235 million in potential sales-based milestone payments Expands Mirum’s leadership in rare liver disea...

2023-08-05 11:42:08 ET Mirum Pharmaceuticals, Inc. (MIRM) Q2 2023 Earnings Conference Call August 03, 2023 4:30 PM ET Company Participants Andrew McKibben – Vice President-Investor Relations and Finance Chris Peetz – President and Chief Executive Office...

2023-08-03 16:41:42 ET Mirum Pharmaceuticals press release ( NASDAQ: MIRM ): Q2 GAAP EPS of -$1.94 misses by $1.14 . Revenue of $37.5M (+114.3% Y/Y) beats by $7.06M . Total operating expenses were $61.8 million for the quarter ended June 30, 2023 in comparison ...

- $37.5 million total revenue, including net product sales for LIVMARLI ® (maralixibat) oral solution of $32.5 million, for second quarter 2023 - Acquiring CHENODAL ® and CHOLBAM ® , advancing Mirum’s leadership in pediatric hepatology with a multi-product fran...

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report second quarter 2023 financial results on Thursday, August 3, 2023. Mirum will also host a conference call to discuss the second quarter 2023 financial results and recent corporate progress. Conference call details:...

First and only medication authorized in Canada for the treatment of cholestatic pruritus in patients with Alagille syndrome. Approval supported by more than six years of LIVMARLI data demonstrating improvements in pruritus and serum bile acids. Data from LIVMARLI clinical trials published...

Mirum to acquire all of Travere’s rights and assets related to Cholbam ® and Chenodal ® Travere to receive up to $445 million with $210 million upfront and up to $235 million in potential sales-based milestones Mirum announces concurrent private placement of $...

• Mirum to acquire all of Travere’s rights and assets related to Cholbam ® and Chenodal ® • Travere to receive up to $445 million with $210 million upfront and up to $235 million in potential sales-based milestones • Ad...

2023-07-09 11:01:40 ET Summary Results from the phase 2b EMBARK study, which is using LIMVARLI for the treatment of patients with biliary atresia, are expected in the 2nd half of 2023. It is expected that the global Biliary Atresia market could grow to $1.69 billion by 2029. R...

New analysis demonstrates bilirubin normalization in PFIC patients treated with LIVMARLI (maralixibat); the only IBAT inhibitor reported to show this effect Sleep improvement observed in patients with PFIC correlated with maralixibat-driven pruritus reduction (selected as Best of EASL) Ma...